Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:administeredBy |
oral medication
|
| gptkbp:alsoKnownAs |
Deferasirox
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
gptkb:V03AC03
|
| gptkbp:CASNumber |
201530-41-8
|
| gptkbp:developedBy |
gptkb:Novartis
|
| gptkbp:hasMolecularFormula |
C21H15N3O4
|
| https://www.w3.org/2000/01/rdf-schema#label |
ICL670
|
| gptkbp:indication |
gptkb:anemia
sickle cell disease other chronic anemias |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
gptkb:Exjade
gptkb:Jadenu |
| gptkbp:mechanismOfAction |
iron chelation
|
| gptkbp:molecularWeight |
373.36 g/mol
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
skin rash
gastrointestinal disturbances increased serum creatinine hepatic dysfunction |
| gptkbp:usedFor |
treatment of chronic iron overload
|
| gptkbp:bfsParent |
gptkb:deferasirox
|
| gptkbp:bfsLayer |
6
|